# CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

> **NCT06834282** · PHASE1 · RECRUITING · sponsor: **CERo Therapeutics Holdings, Inc.** · enrollment: 18 (estimated)

## Conditions studied

- AML
- Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** CER-1236
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Mesna

## Key facts

- **NCT ID:** NCT06834282
- **Lead sponsor:** CERo Therapeutics Holdings, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-07
- **Primary completion:** 2026-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06834282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06834282, "CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06834282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*